Aerie Pharmaceuticals Inc (AERI) Gross Profit Margin starting from the third quarter 2022 to third quarter 2021, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Aerie Pharmaceuticals Inc   (NASDAQ: AERI)


Aerie Pharmaceuticals Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AERI Gross Profit Margin (Sep 30 2022)
Q3 		(Jun 30 2022)
Q2 		(Mar 31 2022)
Q1 		(Dec 31 2021)
Q4 		(Sep 30 2021)
Q3
Y / Y Revenue Change 23.25 %
Seq. Revenue Change 8.46 %
Revenue In Millions $36.13
Gross Profit Margin 80.82 %
Gross Profit Margin Total Ranking # 687
Gross Profit In Millions $29.20
Y / Y Gross Profit Change 36.36 %
Seq. Gross Profit Change -1.25 %


Commenting Third Quarter 2022 Gross Profit Margin
Company's Gross Profit Margin sequentially deteriorated to 80.82 % due to increase in Cost of Sales and despite Revenue increase of 8.46 % to $36 millions.
Company's Gross Profit Margin in III. Quarter, was above company average.


Observing third quarter 2022 results within Biotechnology & Pharmaceuticals industry 10 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 315 to 687.
Learn about Gross Margin
AERI's Gross Profit Margin third quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 11
Healthcare Sector # 105
Overall # 672

Gross Profit Margin Statistics
High Average Low
97.57 % 74.79 % 55.42 %
(Jun 30 2018)   (Mar 31 2019)


AERI Gross Income Trends • More of AERI's Profitabilty Ratios • AERI Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
AERI's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
AERI's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for AERI's Competitors
Gross Profit Margin Profit Margin for Aerie Pharmaceuticals Inc 's Suppliers
Gross Profit Margin Profit Margin for AERI's Customers

You may also want to know
AERI's Annual Growth Rates AERI's Profitability Ratios AERI's Asset Turnover Ratio AERI's Dividend Growth
AERI's Roe AERI's Valuation Ratios AERI's Financial Strength Ratios AERI's Gross Profit Growth
AERI's Roa AERI's Inventory Turnover Ratio AERI's Growth Rates AERI's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2022, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginSep 30 2022 MRQ Gross ProfitSep 30 2022 MRQ Revenue
Agenus Inc  98.65 %$ 22.464  Millions$ 22.772  Millions
Neurocrine Biosciences Inc   98.43 %$ 381.800  Millions$ 387.900  Millions
Exelixis Inc   96.28 %$ 396.433  Millions$ 411.738  Millions
Ginkgo Bioworks Holdings Inc   95.99 %$ 63.738  Millions$ 66.398  Millions
Biocryst Pharmaceuticals Inc   95.33 %$ 72.284  Millions$ 75.827  Millions
Vir Biotechnology Inc   94.06 %$ 352.304  Millions$ 374.557  Millions
Anavex Life Sciences Corp   93.17 %$ 2.048  Millions$ 2.198  Millions
Lineage Cell Therapeutics Inc   92.16 %$ 2.763  Millions$ 2.998  Millions
Zeo Scientifix Inc   81.35 %$ 1.174  Millions$ 1.443  Millions
Biogen Inc   81.28 %$ 2,039.000  Millions$ 2,508.500  Millions
Aerie Pharmaceuticals Inc   80.82 %$ 29.200  Millions$ 36.129  Millions
Gilead Sciences Inc   80.19 %$ 5,647.000  Millions$ 7,042.000  Millions
Seagen Inc   78.81 %$ 402.178  Millions$ 510.300  Millions
Halozyme Therapeutics Inc   77.36 %$ 161.657  Millions$ 208.976  Millions
Amgen Inc   76.13 %$ 5,064.000  Millions$ 6,652.000  Millions
Oyster Point Pharma Inc   75.89 %$ 4.243  Millions$ 5.591  Millions
Orchard Therapeutics Plc  71.53 %$ 4.132  Millions$ 5.777  Millions
Creative Medical Technology Holdings Inc   70.91 %$ 0.039  Millions$ 0.055  Millions
Eiger Biopharmaceuticals Inc   69.41 %$ 2.793  Millions$ 4.024  Millions
Adaptive Biotechnologies Corporation  68.83 %$ 32.923  Millions$ 47.830  Millions
Moderna Inc   67.30 %$ 2,264.000  Millions$ 3,364.000  Millions
Acorda Therapeutics Inc   67.16 %$ 22.506  Millions$ 33.511  Millions
Bio techne Corp  66.62 %$ 179.595  Millions$ 269.595  Millions
Vericel Corporation  65.45 %$ 25.233  Millions$ 38.551  Millions
Sorrento Therapeutics Inc   58.14 %$ 10.117  Millions$ 17.400  Millions
Repligen Corp  56.90 %$ 114.227  Millions$ 200.741  Millions
Xtant Medical Holdings Inc   54.60 %$ 7.896  Millions$ 14.462  Millions
Nanostring Technologies Inc   53.55 %$ 15.818  Millions$ 29.541  Millions
Enzo Biochem Inc  50.75 %$ 3.605  Millions$ 7.103  Millions
Regenxbio Inc   50.61 %$ 13.418  Millions$ 26.512  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.